Royal Bank of Canada
SGMO

Royal Bank of Canada’s SANGAMO THERAPEUTICS INC SGMO Stock Holding History

Royal Bank of Canada’s Portfolio SGMO Stock Details SGMO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q3 		– Sell
-100
Closed -$1K – 7062
2019
Q2 		$1K Sell
100
-21,200
-100% -$225K ﹤0.01% 6739
2019
Q1 		$203K Buy
21,300
+20,900
+5,225% +$213K ﹤0.01% 4350
2018
Q4 		$5K Buy
+400
New +$4.97K ﹤0.01% 6174

Other funds holding SGMO

AC
Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Two Sigma Investments
Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return
Balyasny Asset Management
Balyasny Asset Management Chicago, Illinois $77.1B AUM 42.89% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return
Charles Schwab
Charles Schwab San Francisco, California $654B AUM 26.35% 1-Year Est. Return
VFT
Vanguard Fiduciary Trust Malvern, Pennsylvania $396B AUM

Royal Bank of Canada's SGMO Position: Q1 2026 in Review

Royal Bank of Canada increased its SANGAMO THERAPEUTICS INC (SGMO) stake by 10% in Q1 2026, buying an estimated $165 and bringing the position to 4,519 shares worth $1K. The position accounts for ﹤0.01% of the portfolio, ranked #6945.

Royal Bank of Canada first reported a position in SGMO in Q2 2013 and has held it in 52 quarters since. The position peaked at $695K in Q4 2017. 112 funds tracked by Wall St. Rank hold SGMO as of Q1 2026.

  • Royal Bank of Canada held 4,519 shares of SANGAMO THERAPEUTICS INC worth $1K as of Q1 2026.
  • Royal Bank of Canada bought 414 SANGAMO THERAPEUTICS INC shares in Q1 2026, an estimated $165.
  • SANGAMO THERAPEUTICS INC made up ﹤0.01% of Royal Bank of Canada's portfolio in Q1 2026, its #6945 holding.
  • Royal Bank of Canada first reported a position in SANGAMO THERAPEUTICS INC in Q2 2013 and has held it in 52 quarters since.
  • Royal Bank of Canada's SANGAMO THERAPEUTICS INC position peaked at $695K in Q4 2017.
  • 112 funds tracked by Wall St. Rank held SANGAMO THERAPEUTICS INC as of Q1 2026.

Based on Royal Bank of Canada's 13F filing for Q1 2026, filed 15 May 2026.